Who Supplies Omeprazole to India from SOUTH KOREA

To import finished pharmaceutical formulations containing Omeprazole into India, foreign manufacturers must obtain an Import Registration Certificate from the Central Drugs Standard Control Organization (CDSCO). This process involves submitting an application with comprehensive product details, including composition, manufacturing process, and stability data. The application must be accompanied by a No Objection Certificate (NOC) from the manufacturer, a Certificate of Pharmaceutical Product (CoPP), and a Free Sale Certificate. The CDSCO evaluates the application to ensure compliance with the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The registration process typically takes 6 to 12 months, depending on the completeness of the application and the CDSCO's workload. For Omeprazole formulations under HS Code 30049034, the registration must demonstrate compliance with Indian Pharmacopoeia standards and provide stability data in accordance with ICH guidelines for Zone IV. Additionally, the manufacturer must provide a valid Good Manufacturing Practice (GMP) certificate and a valid manufacturing license. Once registered, the importer must obtain an Import License from the Directorate General of Foreign Trade (DGFT) to legally import the product into India. This license is valid for 5 years and is renewable. The DGFT requires proof of CDSCO registration, a valid Importer Exporter Code (IEC), and compliance with the Foreign Trade Policy.

Upon arrival in India, finished pharmaceutical formulations containing Omeprazole are subject to inspection by customs drug inspectors. The importer must submit a Certificate of Analysis (CoA) from the manufacturer, confirming that each batch meets the specifications outlined in the Indian Pharmacopoeia. Batch-wise testing is mandatory, and the importer must provide stability data in accordance with ICH guidelines for Zone IV. If the batch passes inspection, a release order is issued, allowing the product to enter the market. If the batch fails, the importer must re-export or destroy the product at their expense. The CDSCO-approved laboratory conducts the testing, and the process typically takes 7 to 14 days, depending on the laboratory's workload.

Between 2024 and 2026, the CDSCO has implemented several regulatory updates affecting the import of finished pharmaceutical formulations. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially reducing the demand for imported formulations. However, the PLI scheme does not apply to imported products, maintaining the import duty structure. Bilateral agreements between India and South Korea have facilitated smoother trade relations, including mutual recognition of GMP standards, which may expedite the import process. These agreements aim to enhance the quality and safety of imported pharmaceutical products.

India imports finished Omeprazole formulations to meet the demand for patented and branded products not manufactured domestically. Specific dosage forms, such as delayed-release capsules, may not be produced locally, necessitating imports. Despite a robust domestic pharmaceutical industry, certain specialized formulations are sourced from abroad to fulfill market needs. The market size for Omeprazole formulations in India is substantial, with imports contributing to a significant portion of the total consumption.

The Basic Customs Duty (BCD) on finished pharmaceutical formulations under HS Code 30049034 is 10%. Additionally, a Social Welfare Surcharge (SWS) of 10% of the BCD is applicable. Integrated Goods and Services Tax (IGST) is levied on the assessable value, which includes the CIF value plus applicable duties. There are no exemptions or preferential rates for imports from South Korea. The total landed duty percentage combines these components, impacting the final cost of imported products.

India sources finished Omeprazole formulations from South Korea due to the country's competitive advantages, including adherence to international quality standards and the availability of specialized dosage forms not produced domestically. South Korean manufacturers hold patents for certain formulations, providing unique products to the Indian market. While other suppliers, such as China, Germany, and the United States, also export Omeprazole formulations to India, South Korea's share is notable due to its consistent quality and innovation in pharmaceutical manufacturing.

India imports finished Omeprazole formulations from South Korea due to the availability of patented formulations and specialized dosage forms not produced domestically. South Korean manufacturers offer unique products, such as delayed-release capsules, that fulfill specific market needs in India. The high quality and compliance with international standards make South Korean products a preferred choice for Indian importers seeking reliable and effective pharmaceutical formulations.

Compared to other origins like China, the European Union, and the United States, South Korea offers competitive pricing and high-quality standards. While China may offer lower prices, concerns about quality and regulatory compliance can be a deterrent. The European Union and the United States provide high-quality products but at higher prices. South Korea's unique advantage lies in its ability to offer a balance between quality and cost, making it an attractive source for finished Omeprazole formulations.

Indian importers face several supply chain risks when sourcing finished Omeprazole formulations from South Korea, including single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should consider dual-sourcing strategies, maintain buffer inventories, and establish strong relationships with multiple suppliers. Monitoring currency exchange rates and staying informed about regulatory changes in both countries are also crucial for effective risk management.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP), to manage financial risk.